Inflammatory Cytokines as Risk Factors for a First Venous Thrombosis: A Prospective Population-Based Study

Sverre C. Christiansen1, Inger Anne Næss2, Suzanne C. Cannegieter1, Jens Hammerstrøm2, Frits R. Rosendaal1,3, Pieter H. Reitsma4*

1 Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands, 2 Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, 3 Department of Haematology, Leiden University Medical Center, Leiden, Netherlands, 4 Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, Netherlands

Funding: The study was supported by the Research Council of Norway and by the Netherlands Heart Foundation (grant 2000B185). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Academic Editor: Michael Greaves, University of Aberdeen, United Kingdom

Citation: Christiansen SC, Næss IA, Cannegieter SC, Hammerstrøm J, Rosendaal FR, et al. (2006) Inflammatory cytokines as risk factors for a first venous thrombosis: A prospective population-based study. PLoS Med 3(8): e334. DOI: 10.1371/journal.pmed.0030334

Received: January 19, 2006
Accepted: June 7, 2006
Published: August 22, 2006

DOI: 10.1371/journal.pmed.0030334

Copyright: © 2006 Christiansen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: DVT, deep venous thrombosis; HUNT2, second Norwegian Health Study of Nord-Trøndelag; IL, interleukin; LETS, Leiden Thrombophilia Study; PE, pulmonary embolus; TNF-α, tumour necrosis factor alpha; VT, venous thrombosis

* To whom correspondence should be addressed. E-mail: p.h.reitsma@amc.uva.nl

A B S T R A C T

Background

In case-control studies, elevated levels of interleukins 6 and 8 have been found to be associated with an increased risk of venous thrombosis (VT). Because of the design of these studies, it remained uncertain whether these alterations were a cause or a result of the VT. In order to distinguish between the two, we set out to measure the levels of six inflammatory markers prior to thrombosis in a population-based cohort using a nested case-cohort design.

Methods and Findings

Between August 1995 and June 1997, blood was collected from 66,140 people in the second Norwegian Health Study of Nord-Trøndelag (HUNT2). We identified venous thrombotic events occurring between entry and 1 January 2002. By this date we had registered 506 cases with a first VT; an age- and sex-stratified random sample of 1,464 controls without previous VT was drawn from the original cohort. Levels of interleukins 1β, 6, 8, 10, 12p70, and tumour necrosis factor-α were measured in the baseline sample that was taken 2 d to 75 mo before the event (median 33 mo). Cut-off points for levels were the 80th, 90th, and 95th percentile in the control group. With odds ratios ranging from 0.9 (95% CI: 0.6–1.5) to 1.1 (95% CI: 0.7–1.8), we did not find evidence for a relationship between VT and an altered inflammatory profile.

Conclusions

The results from this population sample show that an altered inflammatory profile is more likely to be a result rather than a cause of VT, although short-term effects of transiently elevated levels cannot be ruled out.

The Editors’ Summary of this article follows the references.
Introduction

Venous thrombosis (VT) is a common and potentially lethal disorder with an estimated incidence of one to three per 1,000 individuals per year [1–3]. The occurrence of venous thrombotic events is influenced by acquired and inherited risk factors (e.g., oral contraception and Factor V Leiden) [4,5]. Combinations of these risk factors further increase the risk to potentially high levels [6].

An important subgroup of risk factors comprises the levels of procoagulant proteins. Several studies have shown that elevated levels of coagulation factors VIII, IX, and XI increase the thrombotic risk [7–9]. Genetic determinants of these high levels have not been found, with the exception of the well-known relation between the ABO blood group and factor VIII levels. It is also possible that increased procoagulant levels are acquired. Experimental studies in human volunteers injected with low-dose endotoxin provide credence for this possibility, as they showed increases in procoagulant protein levels in parallel with an inflammatory response [10–14]. In other studies we have found increased levels of inflammatory markers in patients who had suffered from venous thrombotic disease [15–17]. A scenario that links all these data together is that an acquired inflammatory component is either wholly or in part responsible for the increased levels of at least some of the procoagulant proteins, and, either directly or through this mechanism, causes VT.

The association between inflammation and VT leads to the question of whether inflammation is the cause or the result of VT. There are arguments for both. In favour of a causative role is the above-mentioned possibility that inflammation may increase procoagulant protein levels and thus increase the prothrombotic state of the blood. In addition, it is well known that inflammation may promote tissue factor expression on white blood cells and endothelial cells, thus providing a trigger that may lead to thrombotic disease [18–22]. Other arguments that could go with either role are: 1) the fact that levels of inflammation markers are high in the acute phase of VT and come down afterwards [23], and 2) the frequent occurrence of inflammatory post-thrombotic syndrome [24,25].

Recent case-control studies showed that raised levels of interleukins (IL) 6 and 8 are associated with a 2-fold risk for both first and recurrent thromboembolic events [15,16]. In the Leiden Thrombophilia Study (LETS), both cytokines and tumour necrosis factor alpha (TNF-α) were associated with a 2- to 3-fold increased risk of a first VT, whereas the risk for IL-10 seemed to be decreased [17]. These studies don’t answer the question of whether inflammation is a cause or a result of the event. No prospective studies have yet been undertaken to find out whether increased cytokine levels can be demonstrated in the blood before a venous thromboembolic event has occurred.

We tested the hypothesis that a chronic inflammatory state following a proinflammatory stimulus, regardless of origin, could precede future thrombotic events. In a population-based cohort, we tested levels of cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-12p70) in blood samples obtained at inclusion, and examined the association with the occurrence of subsequent thrombosis.

Methods

Patients and Controls

Between August 1995 and June 1997, all inhabitants aged 20 y or older (n = 94,194) in Nord-Trøndelag County (in Middle Norway) were invited to participate in a population-based health survey (HUNT2) [26]. HUNT2 covers a wide range of topics such as chronic diseases, mental diseases, medication, education, employment, physical activity, and quality of life. The population in this county is considered representative of the rest of the Norwegian population regarding age and sex distribution, morbidity, mortality, and income. It has a low geographic mobility, which makes it suitable for a population survey with subsequent follow-up.

The overall participation rate was 71% (n = 66,140) at baseline (1995–1997), with a median age of 46 y (range 19–103 y) [26].

All consenting participants (n = 66,140) underwent a physical examination and filled out a questionnaire at inclusion. The questionnaire contained questions about risk factors for cardiovascular disease, lifestyle, quality of life, and medication use. In addition, all participants were invited to donate 7.5 ml of blood, and acceptable serum samples were obtained from 65,291 participants (98.7%) [26].

The follow-up for VT was performed as follows: the computerized diagnosis registries of all departments of the only two local hospitals (Levanger and Namsos hospitals) were checked for all in- and outpatient diagnoses containing ICD-9 and ICD-10 diagnostic codes for VT up until 1 January 2002. We completed case finding by searching positive diagnostic procedure codes for venography, duplex ultrasound, and Doppler ultrasound from the registries of the radiology departments in the two hospitals, and patients from Nord-Trøndelag County discharged from St. Olav University Hospital in the neighbouring county with diagnostic codes of VT. This search led to the identification of 2,136 cases with a diagnostic code of VT. Hospital records were obtained, and two physicians (I. Næss and S. Christiansen) validated each case. Cases were included only if they fulfilled the following criteria: deep venous thrombosis (DVT), an intraluminal filling defect or no venous filling on ascending contrast venography; or, no compressible venous segment or no venous flow in popliteal, femoral, or axillar veins on duplex ultrasound; or, a positive computed tomography scan or a positive autopsy; for pulmonary embolus (PE), a ventilation-perfusion scan with one or more segmental or subsegmental perfusion defects with normal ventilation; or, a contrast defect on pulmonary computed tomography scan; or, a positive autopsy. This way, 1,271 cases with a validated diagnosis of definite and probable VT were identified. These records were linked to the HUNT2 cohort, and 798 (63%) cases were identified within the cohort. We excluded all patients with previous VT, enrolment in the HUNT2 cohort after the event, or eye-vein thrombosis (n = 283). As a consequence, 515 cases were included, out of which 506 had blood samples available in which reliable laboratory tests could be performed.

1,505 controls were randomly sampled from the baseline of the HUNT2 cohort by frequency matching to the cases by sex and 5-y age strata. 29 of them were excluded from the subsequent data analysis because they had suffered one or more thrombotic events before the drawing of a blood sample. Another 12 had missing blood samples, leaving 1,464 controls for the analyses.

In a case-cohort design, every person in the source population has the same chance of being included as a control. Since our control group was sampled at baseline, 29 controls later became cases during the follow-up period. The
allows accurate and reproducible measuring of multiple measured using a commercial multiplex bead assay that indications that the time between phlebotomy and freezing transported the same Friday evening [26]. We have no Friday were frozen the following Monday morning after being laboratory at Levanger Hospital and stored in the HUNT were transported the same day in a cooler to the central laboratory.

### Laboratory Measurements

Whole-blood samples were collected from non-fasting participants at entry in the HUNT2 cohort, and within 2 h the serum was separated from blood cells (centrifugation at 1,010 × g) and stored in a refrigerator at 4 °C. All samples were transported the same day in a cooler to the central laboratory at Levanger Hospital and stored in the HUNT biobank there the next morning at −70 °C. Samples taken on Friday were frozen the following Monday morning after being transported the same Friday evening [26]. We have no indications that the time between phlebotomy and freezing affected the levels of the inflammatory mediators.

Serum levels of IL-1β, IL-6, IL-8, IL-12p70, and TNF-α were measured using a commercial multiplex bead assay that allows accurate and reproducible measuring of multiple cytokines in a single small serum aliquot [28,29]. To lower the detection limit of the kit, we used procedures that differed slightly from the recommendations of the manufacturer (BD Biosciences, Alphen aan den Rijn, Netherlands). In brief, 10 μl of thawed serum was mixed with 10 μl of diluted capture bead suspension and 10 μl of phycoerythrin-labelled detection reagent in a sample tube [17]. After 3 h of incubation in darkness, 200 μl of wash buffer was added and the samples were centrifuged at 200 × g. The supernatant was aspirated and the bead pellet resuspended in 150 μl of wash buffer, followed by analysis on a FACSCalibur flow cytometer. (BD Biosciences) [17]. In our hands, the detection limit of these ELISAs was 2.5 pg/ml for all cytokines. With the bead assays, the cytokine concentrations were often near the concentration of the lowest calibrator, and, depending on the analyte, the levels of cytokine in part of the samples remained undetectable. The technicians were not aware of the case or control status of the samples.

In some samples, outlier levels far above the standard curves (up to 4% in cases and 3% in controls) were seen. We believe that these measurements represent artefacts of the procedure, and the results from such samples were excluded prior to the analysis. In 12 controls (0.8%) and nine cases (1.7%), the samples were missing, the volume of serum was too low to perform cytokine assays, or the cytokine measurements failed for technical reasons.

### Statistical Analysis

We used univariate logistic regression to calculate odds ratios and their confidence intervals. Cut-off points were detectable cytokine levels at the 80th, 90th, or 95th percentile calculated in control participants. We stratified for sex, three age categories (<50, 50–69, and ≥70 y of age), time between blood sampling and the event, and whether the event was idiopathic or secondary. A secondary event was defined as an event that occurred after major surgery or trauma, during marked immobility (specified as paresis, paralysis, or >8 h of travel), ante- or postpartum, during use of oral contraceptive pills, or in people with a history of malignancy. Linear regression was used to evaluate the relation between cytokine levels and time until the events in cases.

All analyses were performed with SPSS version 11.0 (SPSS, Chicago, Illinois, United States).

### Consent

Participation was voluntary, and each participant signed a written consent. All surveys were approved by the Norwegian

### Table 1. General Characteristics of Cases and Controls

| Category | Characteristic | Cases n (%) | Controls n (%) |
|----------|----------------|-------------|---------------|
|          | Men            | 228 (45.1)  | 471 (45.8)    |
|          | Women          | 278 (54.9)  | 793 (54.2)    |
|          | Age groups     |             |               |
|          | 20–29          | 12 (2.3)    | 30 (2.1)      |
|          | 30–39          | 17 (3.4)    | 46 (3.1)      |
|          | 40–49          | 53 (10.5)   | 145 (9.9)     |
|          | 50–59          | 72 (14.2)   | 195 (13.3)    |
|          | 60–69          | 99 (19.6)   | 301 (20.6)    |
|          | 70–79          | 169 (33.4)  | 499 (34.1)    |
|          | >80            | 84 (16.6)   | 248 (16.9)    |
|          | Event          |             |               |
|          | DVT            | 320 (63.3)  | 15 (51.7)     |
|          | PE             | 153 (30.2)  | 12 (41.4)     |
|          | Both           | 33 (6.3)    | 2 (6.9)       |
|          | Time from blood sample to event                  |
|          | Median         | 33 mo (2 d to 75 mo) |

*a* The controls were collected at the entry of the HUNT2 study. During the follow-up, 29 controls got a first VT. They are included as both cases and controls. Controls with previous events (i.e., events before the entry of the cohort) were excluded. As a consequence of this design, the 29 controls that later became cases were included in the case group as well as in the control group.

*b* Time in months from the date of blood sampling until the first objective event of VT in cases only.

DOI: 10.1371/journal.pmed.0030334.t001

### Table 2. Levels of Inflammatory Markers in Cases and Controls

| Analyte      | Cases Detectable n (%) | Cases Range (pg/ml) | Cases Median Detectable (pg/ml) | Controls Detectable n (%) | Controls Range (pg/ml) | Controls Median Detectable (pg/ml) |
|--------------|------------------------|---------------------|---------------------------------|---------------------------|------------------------|-----------------------------------|
| TNF-α        | 177 (35)               | 0–4507              | 15.2                            | 499 (34)                  | 0–3603                 | 12.7                              |
| IL-1β        | 289 (59)               | 0–4523              | 49.9                            | 850 (60)                  | 0–4967                 | 46.6                              |
| IL-6         | 194 (39)               | 0–4370              | 35.0                            | 547 (38)                  | 0–4784                 | 39.9                              |
| IL-8         | 498 (99)               | 0–4193              | 17.7                            | 1437 (98)                 | 0–4420                 | 17.9                              |
| IL-10        | 201 (40)               | 0–3786              | 11.0                            | 582 (40)                  | 0–4831                 | 11.8                              |
| IL-12p70     | 283 (58)               | 0–4024              | 36.1                            | 849 (60)                  | 0–4934                 | 30.0                              |

DOI: 10.1371/journal.pmed.0030334.t002
Data Inspectorate and by the Regional Committee for Ethics in Medical Research.

Results

General characteristics of the patients and controls are listed in Table 1. The median age was 70 y in both cases and controls at baseline. 45.1% of the cases were men, compared with 46% in the control group (Table 1). Table 2 summarizes the cytokine and chemokine data. TNF-α, IL-6, and IL-10 were detectable in approximately two-fifths of the samples, whereas IL-1β and IL-12p70 were detectable in three-fifths of the samples. IL-8 was unusual in that it was detectable in almost all cases (99%) and in almost all the controls (98%) as well (Table 2).

Whether markers were detectable or not was similar for cases and controls. Consequently, the odds ratios calculated based on detectable versus undetectable levels were about 1.0, with narrow confidence limits (Table 3). This indicates that a detectable level of any of the markers surveyed in this study was not related to a subsequent VT.

Table 3 lists the odds ratios that were calculated using P80, P90, and P95 as cut-offs. All interleukins demonstrated the same pattern, with no odds ratios exceeding 1.1 for the proinflammatory interleukins (TNF-α, IL-1β, IL-6, IL-8, and IL-12p70) and an odds ratio of 0.9 for the anti-inflammatory IL-10.

We performed a sub-analysis on the samples that were taken within 1 y before the event to see if levels were higher shortly before a thrombosis occurred. They were not; if anything, they tended to be lower. In an analysis of only cases, IL-12 levels, for instance, showed a significant decrease with time closer to the event (Figure 1). IL-1 showed a very similar pattern, while the other cytokines showed no clear trends in values nearer to the event.

Using the 90th percentile in the control participants as a cut-off point for all markers, again no effect was found when men and women were assessed separately, or when a distinction was made between an idiopathic and a secondary event. We found no effect within the three age categories, either (Table 4).

Discussion

We performed the current study to test the hypothesis that circulating levels of proinflammatory cytokines or chemokines are associated with a future event of VT. The data negate this hypothesis, as we found no evidence, neither in a primary analysis nor in post-hoc sub-analyses, that levels of inflammation markers were increased in individuals who later developed VT.

Due to the prospective design of this case-cohort study, there was considerable variation in the time between the blood sampling and the event (this varied between 75 mo and 2 d). Therefore, we could not fully rule out the possibility of a sudden increase of inflammatory markers in hours or days before a first thrombosis. However, this possibility seems less likely, considering the results of a sub-analysis of cases developing VT in the first year after blood sampling. These patients showed no increase whatsoever in cytokine levels shortly before the event.

We found a higher prevalence of detectable cytokines as compared with the prevalence recently found in the control group in the LETS, although the median levels were

---

**Table 3. Odds Ratios and 95% Confidence Intervals for Detectability, and Cut-Offs at the 80th, 90th, and 95th Percentile of Inflammatory Markers**

| Category      | TNF-α OR (95% CI) | IL-1β OR (95% CI) | IL-6 OR (95% CI) | IL-8 OR (95% CI) | IL-10 OR (95% CI) | IL-12p70 OR (95% CI) |
|---------------|-------------------|------------------|-----------------|-----------------|-----------------|---------------------|
| Detectable    | 1.0 (0.8–1.3)     | 1.0 (0.8–1.2)    | 1.1 (0.9–1.3)   | 1.5 (0.6–4.0)   | 1.0 (0.8–1.2)   | 0.9 (0.7–1.2)       |
| P80           | 1.0 (0.8–1.3)     | 1.0 (0.8–1.3)    | 0.9 (0.7–1.2)   | 1.0 (0.7–1.2)   | 1.1 (0.8–1.4)   |
| P90           | 1.1 (0.8–1.5)     | 1.1 (0.8–1.5)    | 1.1 (0.8–1.5)   | 0.9 (0.7–1.3)   | 1.0 (0.7–1.5)   |
| P95           | 1.0 (0.6–1.5)     | 1.1 (0.7–1.8)    | 0.9 (0.5–1.4)   | 1.1 (0.7–1.8)   | 1.0 (0.6–1.6)   | 0.9 (0.6–1.5)       |

---

**Table 4. Odds Ratios and 95% Confidence Intervals for Subgroups with Inflammatory Markers above the 90th Percentile Compared with Those below the 90th Percentile**

| Subgroup       | TNF-α OR (95% CI) | IL-1β OR (95% CI) | IL-6 OR (95% CI) | IL-8 OR (95% CI) | IL-10 OR (95% CI) | IL-12p70 OR (95% CI) |
|----------------|-------------------|------------------|-----------------|-----------------|-----------------|---------------------|
| Men            | 1.2 (0.7–1.9)     | 1.1 (0.6–1.8)    | 1.3 (0.8–2.1)   | 1.1 (0.7–1.8)   | 1.5 (1.0–2.3)   | 1.0 (0.6–1.7)       |
| Women          | 1.0 (0.6–1.6)     | 1.0 (0.6–1.6)    | 0.8 (0.5–1.4)   | 0.9 (0.6–1.5)   | 0.7 (0.4–1.2)   | 1.1 (0.7–1.7)       |
| Unprovoked events | 1.0 (0.7–1.6) | 1.3 (0.8–1.9) | 1.1 (0.7–1.7) | 0.9 (0.6–1.4) | 1.2 (0.8–1.9) | 0.9 (0.6–1.5) |
| Secondary events | 1.1 (0.7–1.7) | 0.9 (0.5–1.4) | 0.9 (0.6–1.5) | 1.2 (0.8–1.9) | 0.9 (0.6–1.5) | 0.8 (0.5–1.3) |
| Age <50 y      | 0.7 (0.3–1.8)     | 1.1 (0.5–2.6)    | 0.7 (0.3–1.9)   | 1.0 (0.4–2.3)   | 0.5 (0.2–1.4)   | 0.9 (0.4–2.2)       |
| Age 50–69 y    | 1.1 (0.7–2.0)     | 0.9 (0.5–1.6)    | 1.0 (0.6–1.8)   | 1.1 (0.7–2.0)   | 0.9 (0.5–1.7)   | 0.9 (0.5–1.7)       |
| Age >70 y      | 1.1 (0.7–1.7)     | 1.1 (0.7–1.8)    | 1.0 (0.6–1.6)   | 1.0 (0.7–1.7)   | 1.1 (0.7–1.8)   | 1.2 (0.8–2.0)       |

DOI: 10.1371/journal.pmed.0030334.t004
Inflammation and Risk of Thrombosis

Acknowledgments

We would like to thank R. Johnsen (NTNU, Trondheim, Norway); J. Holmen, Ø. Krüger, and H. Ellekjaer (HUNT research centre, NTNU, Verdal, Norway); K. Kanneleooning, I. Haarstad, Aa. Nordgaard, and Ø. Stordal (Levanger and Namsoos hospitals, Norway); and N. Andreassen, K. Schi Saetermo, and K. Johnsen (HUNT biobank, Levanger, Norway) for their help in making the data available. We also would like to thank A. P. de Groot for her help with the cytokine assays.

Author contributions. All authors participated in the design of this study within HUNT2. S. Christiansen, I. Næs, and J. Hammerstrom were responsible, in Norway, for data and sample collection from the study participants and for making these available for analysis. P. Reitma was responsible for the cytokine assays. S. Christiansen and S. Cannegieter were responsible for collecting and analyzing the cytokine data. All authors participated in writing the paper and approved the final version of the manuscript.

References

1. Anderson FA Jr., Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, et al. (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151: 933–938.

2. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T (1992) A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 232: 155–160.

3. Oeger (2000) Incidence of venous thromboembolism: A community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83: 657–660.

4. Rosendaal FR (1999). Rosendaal FR (1999) Venous thrombosis: Prevalence and interaction of risk factors. Haemostasis 29 (Suppl S1): 1–9

5. Rosendaal FR (1999) Venous thrombosis: A multicausal disease. Lancet 353: 1167–1173.

6. Vandenbroucke JP, Koster T, Briet E, Reitma PH, Bertina RM, et al. (1994) Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344: 1455–1457.

7. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345: 152–155.

8. Meijers JC, Tekelenburg WL, Bouna BM, Bertina RM, Rosendaal FR (2000) High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342: 696–701.

9. van Hylckama Vlieg AM, van der Linden IK, Bertina RM, Rosendaal FR (2000) High levels of factor IX increase the risk of venous thrombosis. Blood 95: 3678–3682.

10. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, et al. (1990) Experimental endotoxemia in human subjects: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76: 2520–2526.

11. de Vries I, van Deventer SJ, Debets J, Buller HR, ten Cate JW, et al. (1990) Endotoxin-induced cytokines in human septicemia. Adv Exp Med Biol 256: 635–640.

12. Levi M, ten Cate H, Bauer KA, van der Poll T, Edginton TS, et al. (1994) Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93: 114–120.

13. van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ, et al. (1994) Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 179: 1253–1259.

14. van der Poll T, Levi M, van Deventer SJ, ten Cate H, Haagmans BL, et al. (1994) Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83: 446–451.

15. van Aken BE, Reitma PH, Rosendaal FR (2002) Interleukin 6 and venous thrombosis: Evidence for a role of inflammation in thrombosis. Br J Haematol 116: 173–177.

16. van Aken BE, den Heijer M, Bos GM, van Deventer, SJ Reitma PH (2000) Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 83: 526–539.

17. Reitma PH, Rosendaal FR (2004) Activation of innate immunity in patients with venous thrombosis: The Leiden Thrombophilia Study. J Thromb Haemost 2: 619–622.

18. Anquetil C, Weill D, Wautier JL. (1995) Cytokines and thrombosis. J Cardiovasc Pharmacol 25: S13–S19.

19. Muller AB, Zwaveling JH, Smid WM, Maring JK, van Ginkel RJ, et al. (1996) Augmented procoagulant activity in cancer patients, treated with recombinant interferon-gamma in addition to recombinant tumor necrosis factor-alpha and melphalan. Thromb Haemost 76: 897–901.

20. Oses LT, Westvik AB, Joo GB, Okkenhaug C, Kierulf P (1996) Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-15. Cytokine 8: 822–827.

21. Neumann F, Ott I, Marx N, Luther T, Kengst S, et al. (1997) Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagu- lant activity. Arterioscler Thromb Vasc Biol 17: 3399–3405.

Figure 1. Regression Analysis of the Levels of IL-12 in the 12-mo Period before a Thrombotic Event (p = 0.04)

The y-axis shows levels of IL-12 from 85 individuals. The x-axis shows IL-12 levels for those individuals for whom data were available between sampling and thrombotic event. Note that IL-12 levels do not show a tendency to be increased when they are measured closer to the thrombotic event; in fact, the opposite appears to be the case.

DOI: 10.1371/journal.pmed.0030334.g001

Figure 2. Distribution of Levels of IL-12 in the 12-mo Period before Thrombotic Event

The y-axis shows levels of IL-12 from 85 individuals. The x-axis shows IL-12 levels for those individuals for whom data were available between sampling and thrombotic event. Note that IL-12 levels do not show a tendency to be increased when they are measured closer to the thrombotic event; in fact, the opposite appears to be the case.

DOI: 10.1371/journal.pmed.0030334.g002

Figure 3. Regression Analysis of the Levels of IL-12 in the 12-mo Period before a Thrombotic Event (p = 0.04)

The y-axis shows levels of IL-12 from 85 individuals. The x-axis shows IL-12 levels for those individuals for whom data were available between sampling and thrombotic event. Note that IL-12 levels do not show a tendency to be increased when they are measured closer to the thrombotic event; in fact, the opposite appears to be the case.

DOI: 10.1371/journal.pmed.0030334.g003

Figure 4. Distribution of Levels of IL-12 in the 12-mo Period before Thrombotic Event

The y-axis shows levels of IL-12 from 85 individuals. The x-axis shows IL-12 levels for those individuals for whom data were available between sampling and thrombotic event. Note that IL-12 levels do not show a tendency to be increased when they are measured closer to the thrombotic event; in fact, the opposite appears to be the case.

DOI: 10.1371/journal.pmed.0030334.g004
Cytokines: Triggers of clinical thrombotic disease. Thromb Haemost 78: 415–419.

23. Rouman-Klappe EM, Den Heijer M, Janssen MC, van der Vleuten C, Thien T, et al. (2005) The postthrombotic syndrome: Incidence and prognostic value of non-invasive venous examinations in a six-year follow-up study. Thromb Haemost 94: 825–830.

24. Rouman-Klappe EM, Den Heijer M, Janssen MC, Van der Vleuten C, Thien T, et al. (2005) The postthrombotic syndrome: Risk factors and impact on the course of thrombotic disease. J Thrombosis Haemost 3: 2671–2676.

25. Stain M, Schonauer V, Minar E, Bialonczyk C, Hirschl M (2005) The Nord-Trøndelag Health Study 1995–97 (HUNT 2): Objectives, contents, methods and participation. Norweg J Epidemiol 13: 19–32.

26. Holmen JMK, Kruger O, Langhammer A, Lingaa Holmen T, Bratberg GH, et al. (2003) The Nord-Trøndelag Health Study 1995–97 (HUNT 2): Discovery Network, has links to pages of information on venous thrombosis, pulmonary embolism, and the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113: 636–642.

Editors’ Summary

Background. Blood clots (thromboses) are a common medical problem, especially in people who have been immobilized for a variety of reasons, who have other medical or surgical conditions, or who take certain types of drugs such as oral contraceptives. As well as these factors, various genetic changes make it more likely that certain people will develop a thrombosis. The most well known of these genetic changes is a clotting factor, Factor V. Instead of the normal clotting factor V, some people have a variant known as Factor V Leiden, which makes them more likely to develop a thrombosis. These researchers wanted to measure the levels of six cytokines in twenty-five microliters of serum. Clin Chem 49: 1000–1002.

27. Rothman K (2002) Epidemiology: An introduction. Oxford: Oxford University Press. 84–87 pp.

28. Vedrine C, Caraion C, Lambert C, Genin C (2004) Cytometric bead assay of cytokines in sepsis: A clinical evaluation. Cytometry B Clin Cytom 60: 14–22.

29. Tarnok A, Hambsch J, Chen R, Varro R (2003) Cytometric bead array to measure six cytokines in twenty-five microliters of serum. Clin Chem 49: 1000–1002.

30. Exhler WB, Keller ET (2000) Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51: 245–270.

31. Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, et al. (1998) Monocyte cytokine production in an elderly population: Effect of age and inflammation. J Gerontol A Biol Sci Med Sci 53: M20–M26.

32. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, et al. (2002) Coagulation factors, inflammation markers, and venous thrombembolism: The longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113: 636–642.

22. ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJ (1997) Cytokines: Triggers of clinical thrombotic disease. Thromb Haemost 78: 415–419.

23. Rouman-Klappe EM, Den Heijer M, Janssen MC, van der Vleuten C, Thien T, et al. (2005) The postthrombotic syndrome: Incidence and prognostic value of non-invasive venous examinations in a six-year follow-up study. Thromb Haemost 94: 825–830.

24. Rouman-Klappe EM, Den Heijer M, Janssen MC, Van der Vleuten C, Thien T, et al. (2005) The postthrombotic syndrome: Risk factors and impact on the course of thrombotic disease. J Thrombosis Haemost 3: 2671–2676.

25. Stain M, Schonauer V, Minar E, Bialonczyk C, Hirschl M (2005) The Nord-Trøndelag Health Study 1995–97 (HUNT 2): Objectives, contents, methods and participation. Norweg J Epidemiol 13: 19–32.

What Was This Study Done? Previous studies have shown that the levels of inflammatory substances, known as cytokines, are raised around the time of a thrombosis. However, because of the design of these studies it was not clear whether these alterations were a cause or a result of the thrombosis. These researchers wanted to measure the levels of six cytokines before thrombosis in a large group of people and follow them to see if any particular level of cytokine made it more likely that they would go on to develop a thrombosis.

What Did the Researchers Do and Find? During a three-year period between August 1995 and June 1997, blood was collected from 66,140 people in the second Norwegian Health Study of Nord-Trøndelag (HUNT2). Anyone who had a thrombosis between the start of the study and the beginning of 2002 was identified—506 people in all. Blood samples, taken from these people (cases) between two days and 75 months before the thrombosis happened, were used to measure levels of a number of different cytokines (abbreviated to IL-1β, IL-6, IL-8, IL-10, IL12p70, and tumor necrosis factor alpha [TNF-α]). These levels were then compared with those in samples also taken earlier from 1,464 people who were similar to the cases but had no thrombosis (controls). The authors found no evidence for a relationship between the chance of getting a thrombosis and a change in any of these markers of inflammation.

What Do These Findings Mean? It seems unlikely that any long-term changes in levels of cytokines make any difference as to whether or not people develop a thrombosis. Hence, any changes seen in previous studies are most likely to have been the result of the thrombosis. However, the researchers could not rule out that changes occurred in the hours or days immediately before the thrombosis, although that seems unlikely. In any case, the levels of these cytokines do not seem to be useful as a clinical tool to predict who is at risk of thrombosis.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/101371/journal.pmed.0030334.

• MedlinePlus encyclopedia entries on deep venous thrombosis and pulmonary embolus

• Omni, a health information service in the UK run by the Resource Discovery Network, has links to pages of information on venous thrombosis

• The HUNT studies are described in this Web site

Inflammation and Risk of Thrombosis

Why Was This Study Done? Previous studies have shown that the levels of inflammatory substances, known as cytokines, are raised around the time of a thrombosis. However, because of the design of these studies it was not clear whether these alterations were a cause or a result of the thrombosis. These researchers wanted to measure the levels of six cytokines before thrombosis in a large group of people and follow them to see if any particular level of cytokine made it more likely that they would go on to develop a thrombosis.

What Did the Researchers Do and Find? During a three-year period between August 1995 and June 1997, blood was collected from 66,140 people in the second Norwegian Health Study of Nord-Trøndelag (HUNT2). Anyone who had a thrombosis between the start of the study and the beginning of 2002 was identified—506 people in all. Blood samples, taken from these people (cases) between two days and 75 months before the thrombosis happened, were used to measure levels of a number of different cytokines (abbreviated to IL-1β, IL-6, IL-8, IL-10, IL12p70, and tumor necrosis factor alpha [TNF-α]). These levels were then compared with those in samples also taken earlier from 1,464 people who were similar to the cases but had no thrombosis (controls). The authors found no evidence for a relationship between the chance of getting a thrombosis and a change in any of these markers of inflammation.

What Do These Findings Mean? It seems unlikely that any long-term changes in levels of cytokines make any difference as to whether or not people develop a thrombosis. Hence, any changes seen in previous studies are most likely to have been the result of the thrombosis. However, the researchers could not rule out that changes occurred in the hours or days immediately before the thrombosis, although that seems unlikely. In any case, the levels of these cytokines do not seem to be useful as a clinical tool to predict who is at risk of thrombosis.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/101371/journal.pmed.0030334.

• MedlinePlus encyclopedia entries on deep venous thrombosis and pulmonary embolus

• Omni, a health information service in the UK run by the Resource Discovery Network, has links to pages of information on venous thrombosis

• The HUNT studies are described in this Web site